This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Accelerated Positive Trend On Evotec's Revenues And Profits

HAMBURG, Germany, Nov. 11, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today reported financial results and a corporate update for the first nine months of 2010.

Recent Highlights:

Strong improvement of key financial results
  • Evotec reports continued strong revenue growth of 33% and a positive operating result of € 1.0 m for the first nine months of 2010 (compared to € 32.9 m loss in the first nine months of 2009)
  • Strong Q3 results with 33% improvement in revenues and a positive operating result of € 0.7 m (compared to € 3.8 m loss in Q3 2009)
  • Following cash flow positive third quarter liquidity improved compared to the end of H1 2010 to € 70.2 m (+ € 2.3 m)

Several new discovery alliances initiated; progress and milestone achievements in current partnerships
  • New ion channel hit identification agreement with Almirall
  • Fragment-based drug discovery alliance with Shionogi (after period-end)
  • Pain alliance with Apeiron Biologics (after period-end)
  • Milestone achievement with Boehringer Ingelheim
  • Good progress in many alliances (e.g. Vifor, Genentech)
  • Excellent capacity utilisation

Proprietary research programmes advancing
  • Focused research investments in proprietary platform technologies and selected discovery programmes
  • Evaluation of indication for EVT 401 ongoing
  • Increased research commitment to metabolic disease capability since closing of DeveloGen acquisition

Product development partnerships on track; first license agreement for EVT 201
  • Phase II with EVT 101 in treatment-resistant depression with Roche on track
  • Jingxin Pharma in-licenses Evotec's insomnia candidate EVT 201 for development in China (after period-end)

DeveloGen acquisition completed
  • 6,750,014 new shares were issued from authorised capital in Q4 as consideration for the transaction

Financial guidance for 2010 confirmed
  • More than 20% revenue growth expected for the full year 2010, leading to revenues of € 52 to 54 m
  • Strong 2010 order book (October 2010: € 51 m; +31% over 2009) supports growth target
  • Liquidity guidance of >€ 64 m at year-end confirmed despite cash required for the acquisition of DeveloGen

Financial outlook 2011 and beyond shows continued growth
  • Revenue growth of more than 15% expected into 2011
  • Well on track for sustainable profitability latest in 2012


Strong improvement of key financial results

During the first nine months of 2010 Evotec's drug discovery alliances continued to grow significantly. Supported by milestone achievements, revenues increased by 33% to € 38.8 m (2009: € 29.1 m). Gross margin was strong at 44.0% (2009: 38.3%). Following the implementation of Evotec's Action Plan 2012, and successful partnering, R&D expenses declined by 79% to € 4.2 m (2009: € 19.5 m), and SG&A costs by 12% to € 11.6 m (2009: € 13.1 m). On this basis, the operating result was positive at € 1.0 m (2009: € 32.9 m loss). Liquidity including cash, cash equivalents and investments at the end of September 2010 increased from end of June 2010 to € 70.2 m.


Several new discovery alliances initiated; progress and milestone achievements in current partnerships

Due to its scale, strong platform of technologies combined with disease biology know-how and excellent project management, as well as its strong reputation in the industry, Evotec is ideally positioned as the partner of choice for integrated drug discovery alliances with the pharmaceutical and biotech industry. The Company signed a number of new important contracts during the third quarter and made good progress in many of its current programmes. Within its collaboration with Boehringer Ingelheim a third milestone for 2010 was achieved in July.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,837.84 +25.65 0.14%
S&P 500 2,087.19 -1.95 -0.09%
NASDAQ 5,104.0630 +1.2550 0.02%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs